Abstract |
H5N1 avian influenza continues to be a potential pandemic threat. Several vaccine candidates based on potentially pandemic influenza strains and antiviral drugs have been tested in preclinical and clinical studies. The data obtained so far have shown some promise, but have also revealed some shortcomings with both of these approaches. We have identified and characterized an H5N1 neuraminidasespecific monoclonal antibody which specifically inhibits N1 neuraminidase activity of highly pathogenic avian influenza (HPAI) strains from clades 1 and 2. We have also shown the protective efficacy of this antibody in animal challenge models using homologous virus. Specific and effective inhibition of N1 NA could make this mAb a useful therapeutic tool in the treatment of human infection, in particular with oseltamivirand zanamivir-resistant strains of HPAI.
|
Authors | Yoko Shoji, Jessica A Chichester, Gene A Palmer, Christine E Farrance, Robert Stevens, Michelle Stewart, Lauren Goldschmidt, Varough Deyde, Larisa Gubareva, Alexander Klimov, Vadim Mett, Vidadi Yusibov |
Journal | Human vaccines
(Hum Vaccin)
2011 Jan-Feb
Vol. 7 Suppl
Pg. 199-204
ISSN: 1554-8619 [Electronic] United States |
PMID | 21922687
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Neutralizing
- Antibodies, Viral
- Viral Proteins
- NA protein, influenza A virus
- Neuraminidase
|
Topics |
- Animals
- Antibodies, Monoclonal
(administration & dosage, immunology)
- Antibodies, Neutralizing
(administration & dosage, immunology)
- Antibodies, Viral
(administration & dosage, immunology)
- Body Weight
- Disease Models, Animal
- Female
- Influenza A Virus, H5N1 Subtype
(immunology)
- Male
- Mice
- Mice, Inbred BALB C
- Neuraminidase
(immunology)
- Orthomyxoviridae Infections
(prevention & control)
- Rodent Diseases
(prevention & control)
- Survival Analysis
- Viral Proteins
(immunology)
|